Psoriasis | Unmet Need | US/EU | 2016


Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial potential. Significant opportunities exist for emerging therapies to differentiate themselves by addressing important unmet needs such as improved efficacy outcomes on more-stringent measures, a better risk-benefit profile, more-convenient delivery formulation, and an oral drug with efficacy comparable to that of the biologics.